Previous Article | Next Article ![]()
Journal of Virology, April 1999, p. 3162-3168, Vol. 73, No. 4
Department of Molecular and Experimental
Medicine, The Scripps Research Institute, La Jolla, California
92037
Received 25 September 1999/Accepted 7 January 1999
Interferon gamma (IFN-
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Recombinant Duck Interferon Gamma Inhibits Duck Hepatitis B Virus
Replication in Primary Hepatocytes
and
), which has been cloned in several
mammalian species and recently in birds, plays a critical role in
modulating immune system function. IFN-
and tumor necrosis factor
alpha (TNF-
) have been shown to be crucial in the pathogenesis of
viral hepatitis and in the transient disappearance of hepatitis B virus
(HBV) from the liver after adoptive transfer of HBV-specific cytotoxic
T lymphocytes into HBV-transgenic mice. Similar studies in the
natural animal hosts of related hepadnaviruses have been limited
because the corresponding probes and recombinant cytokines were not
available. For this reason, we initiated studies to clone and
characterize cytokines from the duck, the natural host of the duck
hepatitis B virus (DHBV). We describe here the cDNA cloning and initial
characterization of the IFN-
homologue of ducks (DuIFN-
). The
DuIFN-
cDNA codes for a predicted mature protein of 145 amino acids
with a molecular mass of 16.6 kDa. The precursor protein has 67%
identity with the previously cloned chicken IFN-
and 21 to 34%
identity with mammalian IFN-
. Recombinant DuIFN-
induces the
transcription of several IFN-inducible genes including IFN regulatory
factor 1 and guanylate-binding protein, and it exhibits antiviral
activity that protects duck cells from vesicular stomatitis virus-mediated lysis. Importantly, treatment of primary duck
hepatocytes with recombinant DuIFN-
inhibits DHBV replication
in a dose-dependent fashion. Time course analysis revealed that IFN-
treatment does not affect initial covalently closed circular DNA
(cccDNA) conversion but inhibits the synthesis of progeny cccDNA by amplification.
*
Corresponding author. Mailing address: Department of
Molecular and Experimental Medicine, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (619) 784-8228. Fax: (619) 784-2160. E-mail: fchisari{at}scripps.edu.
Manuscript no. 11943-MEM from The Scripps Research Institute.
Present address: Department of Internal Medicine II, Molecular
Biology, University Hospital Freiburg, D-79106 Freiburg, Germany.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|